The increased expression of CCL5 was also observed in U87i and U87w lysates in control patients (by 5.88-fold and 6.04-fold respectively) and in mild AD patients (by 10.21-fold and 7.70-fold respectively) versus respective U87 lysates in BBB models without PBMCs (Table 3). This evidence concerns the gene CCL5 and Alzheimer disease.